In this retrospective analysis of a large, real-world cohort of ICI-treated NSCLC patients, we determined that treatment with ICI-chemo compared to ICI-mono led to no difference in long-term progression-free or overall survival across PD-L1 levels. The gene discussed is CD274; the disease is non-small cell lung carcinoma.